IDOL
Research type
Research Study
Full title
A Phase I/Ib trial of Idetrexed (a novel α-folate receptor-mediated thymidylate synthase inhibitor) in combination with Olaparib (a PARP inhibitor) at different doses in patients with ovarian cancer.
IRAS ID
1008393
Contact name
Udai Banerji
Contact email
Sponsor organisation
The Institute of Cancer Research
Research summary
Purpose of the Study:
This clinical trial aims to evaluate the effectiveness and safety of combining olaparib and idetrexed to treat ovarian cancer. Ovarian cancer requires new treatment strategies to improve patient outcomes.
Current Treatments and Challenges:
Platinum-based therapies are standard for ovarian cancer. Although initially effective, many patients develop resistance, leading to treatment failure and disease progression.
What is Olaparib?
Olaparib disrupts cancer cells’ ability to repair their DNA, making it difficult for them to survive and grow.
What is Idetrexed?
Idetrexed targets specific proteins in cancer cells, helping to stop their growth and spread. It binds to the alpha folate receptor, often over-expressed in high-grade serous ovarian cancer (HGSOC), allowing for targeted drug delivery to cancer cells.
Why Combine These Drugs?
Combining olaparib and idetrexed offers a new approach to overcoming resistance seen with platinum-based therapies. This dual attack on cancer cells could enhance treatment effectiveness and improve survival and quality of life for patients. Targeting the alpha folate receptor with idetrexed ensures specific delivery to cancer cells, potentially increasing efficacy.
Study Design:
Participants: Ovarian cancer patients meeting specific criteria.
Treatment Plan: Patients receive olaparib and idetrexed together, with doses and schedules monitored by healthcare professionals.
Monitoring: Regular check-ups and tests track patients’ responses and any side effects.
Expected Outcomes:
The trial aims to ensure safety and tolerability when idetrexed and olaparib are used together in treating HGSOC.
Why This Study Matters:
With many patients developing resistance to current platinum-based therapies, there is a pressing need for new treatments. This combination therapy could offer a new, effective option, providing targeted treatment and renewed hope.REC name
London - Surrey Borders Research Ethics Committee
REC reference
25/LO/0172
Date of REC Opinion
16 May 2025
REC opinion
Further Information Favourable Opinion